Hsin‐Yi Tseng

1.5k total citations
36 papers, 1.1k citations indexed

About

Hsin‐Yi Tseng is a scholar working on Molecular Biology, Epidemiology and Cell Biology. According to data from OpenAlex, Hsin‐Yi Tseng has authored 36 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 11 papers in Epidemiology and 9 papers in Cell Biology. Recurrent topics in Hsin‐Yi Tseng's work include Autophagy in Disease and Therapy (9 papers), Cell death mechanisms and regulation (6 papers) and Histone Deacetylase Inhibitors Research (6 papers). Hsin‐Yi Tseng is often cited by papers focused on Autophagy in Disease and Therapy (9 papers), Cell death mechanisms and regulation (6 papers) and Histone Deacetylase Inhibitors Research (6 papers). Hsin‐Yi Tseng collaborates with scholars based in Australia, China and Taiwan. Hsin‐Yi Tseng's co-authors include Xu Dong Zhang, Lei Jin, Chen Chen Jiang, Su Guo, Kwang Hong Tay, Peter Hersey, Amanda Croft, Rick F. Thorne, Fritz Lai and Xu Guang Yan and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Hsin‐Yi Tseng

35 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hsin‐Yi Tseng Australia 21 776 302 251 235 234 36 1.1k
Emiliano Dalla Italy 18 836 1.1× 278 0.9× 217 0.9× 215 0.9× 83 0.4× 39 1.2k
Kirill V. Rosen Canada 19 875 1.1× 183 0.6× 227 0.9× 130 0.6× 192 0.8× 37 1.2k
Jinmei Yu China 15 616 0.8× 211 0.7× 209 0.8× 190 0.8× 209 0.9× 28 1.1k
Estelle Saland France 18 902 1.2× 329 1.1× 232 0.9× 173 0.7× 91 0.4× 28 1.4k
Niklas K. Finnberg United States 18 678 0.9× 234 0.8× 240 1.0× 453 1.9× 147 0.6× 40 1.4k
Karen Man‐Fong Sze Hong Kong 17 635 0.8× 309 1.0× 225 0.9× 182 0.8× 108 0.5× 32 1.1k
Séverine Cathelin Canada 16 1.0k 1.3× 269 0.9× 104 0.4× 285 1.2× 149 0.6× 29 1.4k
Annalisa Lonetti Italy 24 824 1.1× 179 0.6× 123 0.5× 157 0.7× 146 0.6× 57 1.5k
Aparna C. Ranganathan United States 12 747 1.0× 288 1.0× 226 0.9× 126 0.5× 371 1.6× 14 1.2k
Marta Martínez Spain 16 717 0.9× 299 1.0× 128 0.5× 177 0.8× 83 0.4× 28 1.2k

Countries citing papers authored by Hsin‐Yi Tseng

Since Specialization
Citations

This map shows the geographic impact of Hsin‐Yi Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsin‐Yi Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsin‐Yi Tseng more than expected).

Fields of papers citing papers by Hsin‐Yi Tseng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsin‐Yi Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsin‐Yi Tseng. The network helps show where Hsin‐Yi Tseng may publish in the future.

Co-authorship network of co-authors of Hsin‐Yi Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of Hsin‐Yi Tseng. A scholar is included among the top collaborators of Hsin‐Yi Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsin‐Yi Tseng. Hsin‐Yi Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tseng, Hsin‐Yi, Sara Alavi, Stuart Gallagher, et al.. (2024). BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti‐CTLA‐4 treatment. Pigment Cell & Melanoma Research. 37(6). 744–751. 2 indexed citations
2.
3.
Emran, Abdullah Al, Hsin‐Yi Tseng, Dilini Gunatilake, et al.. (2021). A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. Journal of Investigative Dermatology. 141(9). 2238–2249.e12. 10 indexed citations
4.
Ahmed, Farzana, Hsin‐Yi Tseng, Antonio Ahn, et al.. (2021). Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. Journal of Investigative Dermatology. 142(5). 1444–1455.e10. 16 indexed citations
5.
Tseng, Hsin‐Yi, Abdullah Al Emran, Dilini Gunatilake, et al.. (2020). Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma. International Journal of Cancer. 147(8). 2176–2189. 20 indexed citations
6.
McGuire, Helen M., Abdullah Al Emran, Hsin‐Yi Tseng, et al.. (2020). Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology. 11. 372–372. 20 indexed citations
7.
Tseng, Hsin‐Yi, et al.. (2017). Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression. Oncogenesis. 6(4). e313–e313. 24 indexed citations
8.
Thorburn, Alison N., Hsin‐Yi Tseng, Chantal Donovan, et al.. (2016). TLR2, TLR4 AND MyD88 Mediate Allergic Airway Disease (AAD) and Streptococcus pneumoniae-Induced Suppression of AAD. PLoS ONE. 11(6). e0156402–e0156402. 28 indexed citations
9.
Liu, Xiao Ying, Fritz Lai, Xu Guang Yan, et al.. (2015). RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research. 75(8). 1736–1748. 58 indexed citations
10.
Tseng, Hsin‐Yi, et al.. (2014). Adipocytes Contribute to Resistance of Human Melanoma Cells to Chemotherapy and Targeted Therapy. Current Medicinal Chemistry. 21(10). 1255–1267. 36 indexed citations
11.
Dong, Lei, Lei Jin, Hsin‐Yi Tseng, et al.. (2013). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene. 33(39). 4756–4766. 33 indexed citations
12.
Lai, Fritz, Su Guo, Lei Jin, et al.. (2013). Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death and Disease. 4(6). e655–e655. 39 indexed citations
13.
Ye, Yan, Qun Li, Wang Hu, et al.. (2013). Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. Translational Oncology. 6(4). 470–IN15. 6 indexed citations
14.
Croft, Amanda, Hsin‐Yi Tseng, Su Guo, et al.. (2013). Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene. 33(20). 2577–2588. 21 indexed citations
15.
Tay, Kwang Hong, Qi Luan, Amanda Croft, et al.. (2013). Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress. Cellular Signalling. 26(2). 287–294. 77 indexed citations
16.
Croft, Amanda, Kwang Hong Tay, Suzanah C. Boyd, et al.. (2013). Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. Journal of Investigative Dermatology. 134(2). 488–497. 64 indexed citations
17.
Tay, Kwang Hong, Lei Jin, Hsin‐Yi Tseng, et al.. (2012). Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death and Disease. 3(6). e337–e337. 32 indexed citations
18.
Guo, Su, Xiuli Guo, Rongrong Yang, et al.. (2012). MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 32(15). 1910–1920. 186 indexed citations
19.
Tseng, Hsin‐Yi, Li Hua Chen, Yan Ye, et al.. (2012). The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis. 33(10). 1871–1881. 22 indexed citations
20.
Liu, Hao, Chen Chen Jiang, Amanda Croft, et al.. (2009). 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Molecular Cancer. 8(1). 122–122. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emiliano Dalla Breakdown of academic impact, for papers by Kirill V. Rosen Breakdown of academic impact, for papers by Jinmei Yu Breakdown of academic impact, for papers by Estelle Saland Breakdown of academic impact, for papers by Niklas K. Finnberg Breakdown of academic impact, for papers by Karen Man‐Fong Sze Breakdown of academic impact, for papers by Séverine Cathelin Breakdown of academic impact, for papers by Annalisa Lonetti Breakdown of academic impact, for papers by Aparna C. Ranganathan Breakdown of academic impact, for papers by Marta Martínez
Rankless by CCL
2026